AtriCure Inc. (ATRC) Receives Consensus Rating of “Hold” from Analysts
Shares of AtriCure Inc. (NASDAQ:ATRC) have earned a consensus recommendation of “Hold” from the eleven research firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $24.33.
A number of research analysts have commented on the stock. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price objective (down from $25.00) on shares of AtriCure in a research note on Tuesday, January 16th. TheStreet downgraded shares of AtriCure from a “c-” rating to a “d+” rating in a research note on Wednesday, November 29th. ValuEngine downgraded shares of AtriCure from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. Canaccord Genuity reduced their price target on shares of AtriCure from $28.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, November 2nd. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $24.00 price target on shares of AtriCure in a research report on Sunday, December 10th.
AtriCure (NASDAQ:ATRC) opened at $15.31 on Friday. AtriCure has a 52 week low of $14.88 and a 52 week high of $25.18. The company has a current ratio of 2.28, a quick ratio of 1.65 and a debt-to-equity ratio of 0.20. The company has a market cap of $518.84, a price-to-earnings ratio of -15.01 and a beta of 0.39.
Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. bought a new stake in AtriCure in the 3rd quarter valued at about $771,000. Skylands Capital LLC bought a new stake in AtriCure in the 4th quarter valued at about $1,368,000. State Street Corp lifted its position in AtriCure by 4.0% in the 2nd quarter. State Street Corp now owns 617,405 shares of the medical device company’s stock valued at $14,971,000 after purchasing an additional 23,790 shares during the last quarter. UBS Asset Management Americas Inc. bought a new stake in AtriCure in the 2nd quarter valued at about $315,000. Finally, Vanguard Group Inc. lifted its position in AtriCure by 3.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,446,732 shares of the medical device company’s stock valued at $35,083,000 after purchasing an additional 52,761 shares during the last quarter. Hedge funds and other institutional investors own 86.41% of the company’s stock.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.